Cargando…
Perspectives on Repurposed Drugs Based on Globally Accepted Therapeutic Guidelines to Combat SARS-CoV-2 Infection
A beta coronavirus was identified in Wuhan, China, in December 2019 and was named severe acute respiratory syndrome coronavirus-2. It spread globally at a rapid rate and killed innumerable people. The SARS-CoV-2 infection, also called coronavirus disease 2019, was declared a pandemic by WHO on March...
Autor principal: | Rosalia, Rina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850415/ https://www.ncbi.nlm.nih.gov/pubmed/33536792 http://dx.doi.org/10.2147/DHPS.S272411 |
Ejemplares similares
-
Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements
por: Pandey, Abhjieet, et al.
Publicado: (2020) -
Computational approaches for drug repositioning and repurposing to combat SARS-CoV-2 infection
por: Panda, Subhamay, et al.
Publicado: (2022) -
A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval
por: Ashour, Nada A, et al.
Publicado: (2022) -
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2
por: Xue, Yiying, et al.
Publicado: (2023) -
Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
por: Tabassum, Neha, et al.
Publicado: (2020)